RIGL
Rigel PharmaceuticalsยทNASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
RIGL Profile
Rigel Pharmaceuticals, Inc.
A biotech company that developing novel small molecule drugs for hematologic disorders, cancer, and rare immune diseases
611 Gateway Boulevard, Suite 900, South San Francisco, California 94080
--
Rigel Pharmaceuticals, Inc., was founded in Delaware on June 14, 1996. The company is a biotechnology company dedicated to discovering, developing and delivering new therapies that significantly improve the lives of patients with hematological diseases and cancer. The Company's first FDA-approved product is TAVALISSE (disodium hexahydrate fortamatinib) tablets, the only approved oral spleen tyrosine kinase (SYK) inhibitor for the treatment of adult patients with chronic immune thrombocytopenia (ITP) who have not responded adequately to previous treatment. The company's second FDA-approved product is REZLIDHIA (olutasidenib) capsules for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with susceptible isocitrate dehydrogenase 1 (IDH) mutations detected in FDA-approved trials.
